- Antimicrobial Resistance
- Contact
- Home
- Legal
- News
- Pipeline
- Platform
- Quick Contact Content
- Team
- Nosopharm welcomes Jacques Biton and Frédéric Hammel to its supervisory board
- Nosopharm and Evotec enter into collaboration to accelerate development of novel antibiotics
- Job alert: Nosopharm opens two new R&D positions to be filled in September 2019
- Nosopharm appoints Dr Sarah Gould as chief development officer
- ASM Microbe 2018: Nosopharm to present new first-in-class clinical candidate to tackle Enterobacteriaceae infections
- Nosopharm renews its partnership with Inra
- ANTIBIOTIC RESISTANCE : NOSOPHARM AND THE UNIVERSITY OF ILLINOIS AT CHICAGO DESCRIBE MECHANISM OF ACTION OF NEW CLASS OF ANTIBIOTICS IN MOLECULAR CELL
- Nosopharm receives €1 million loan from Bpifrance
- Nosopharm bolsters supervisory board
- Nosopharm raises €2.4 million ($2.6M) to develop a novel antibiotic class
- Nosopharm joins European Gram-negative Antibacterial Engine (ENABLE) project to combat antibiotic resistance
- Nosopharm hires four new international experts to its scientific advisory board
- Nosopharm shares scientific data on Odilorhabdins, a novel antibacterial class with the potential to combat antibiotic resistance
- Nosopharm receives EUR 870,000 (USD 1.18 million) to help combat antibiotic resistance
- Nosopharm and INRA strengthen their partnership in the field of medicinal mining of the microbial genera Xenorhabdus and Photorhabdus
english french